

Methafoli 10 Tablet

Methafoli 10 Tablet

Composition:

Each uncoated tablet contains:

- **Methoxsalen IP** ... 10 mg
- **Excipients** ... q.s.

Dosage Form:

Tablet

Therapeutic Category:

Psoralen (Photosensitizing Agent) – For Photochemotherapy (PUVA)

Pharmacology & Mechanism of Action:

Methoxsalen is a naturally occurring furocoumarin compound that exerts its effects by intercalating with DNA. Upon activation by UVA (320–400 nm) light, it forms covalent bonds with pyrimidine bases in DNA, leading to cross-linking and inhibition of DNA synthesis and cell replication. This action reduces abnormal proliferation of skin cells and modulates immune responses.

Indications:

- Vitiligo
- Psoriasis
- Cutaneous T-cell lymphoma (CTCL)
- Other skin disorders responsive to PUVA therapy

Dosage & Administration:

- **Adults:** Usually 0.6 mg/kg body weight, administered orally 1.5 to 2 hours before UVA exposure
- Dose and UVA exposure time should be individualized based on skin type and clinical condition
- Patients should wear UVA-protective eyewear during and after exposure for at least 24 hours

Contraindications:

- Hypersensitivity to methoxsalen or psoralens
- History of photosensitivity disorders (e.g., lupus erythematosus, porphyria)
- Presence of melanoma or invasive skin cancer
- Hepatic impairment or cataracts

Warnings & Precautions:

- Must be used under physician supervision trained in photochemotherapy
- Avoid sun exposure for 24–48 hours post-dose to prevent severe burns
- Regular ophthalmic examination recommended during long-term therapy
- Use sunscreen on non-affected areas during UVA exposure
- Caution in patients with hepatic dysfunction or cardiovascular disease

Adverse Effects:

- Common: Nausea, pruritus, erythema, headache
- Photosensitivity reactions, severe sunburns, hyperpigmentation
- Long-term use may increase the risk of skin aging or carcinogenesis

Drug Interactions:

- Concomitant use with other photosensitizing agents (e.g., tetracyclines, sulfonamides) may increase risk of phototoxicity
- Avoid alcohol as it may potentiate nausea
- CYP450 interactions may alter plasma levels in hepatic impairment

Overdose:

- Symptoms: Severe burns, erythema, GI upset
- Management: Supportive care, avoidance of sunlight, symptomatic treatment

Storage:

Store below 25°C in a cool, dry place
Protect from light and moisture
Keep out of reach of children

Manufactured in India for:

CafoliTM
L I F E C A R E
Cafoli Lifecare Pvt. Ltd.

(An ISO 9001: 2015 Certified Co.)

Plot no.: 367-FF, Industrial Area Phase-I,
Panchkula-134113

TM: Trademark Applied for